J Korean Med Sci.  2020 Apr;35(18):e176. 10.3346/jkms.2020.35.e176.

Perspectives of Immune Therapy in Coronavirus Disease 2019

• Gasparyan AY
• Misra DP
• Yessirkepov M
• Zimba O

• KMID: 2500222
• DOI: http://doi.org/10.3346/jkms.2020.35.e176

Abstract

The global fight against coronavirus disease 2019 (COVID-19) is largely based on strategies to boost immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent its severe course and complications. The human defence may include antibodies which interact with SARS-CoV-2 and neutralize its aggressive actions on multiple organ systems. Protective cross-reactivity of antibodies against measles and other known viral infections has been postulated, primarily as a result of the initial observations of asymptomatic and mild COVID-19 in children. Uncontrolled case series have demonstrated virus-neutralizing effect of convalescent plasma, supporting its efficiency at early stages of contracting SARS-CoV-2. Given the variability of the virus structure, the utility of convalescent plasma is limited to the geographic area of its preparation, and for a short period of time. Intravenous immunoglobulin may also be protective in view of its nonspecific antiviral and immunomodulatory effects. Finally, human monoclonal antibodies may interact with some SARS-CoV-2 proteins, inhibiting the virus-receptor interaction and prevent tissue injury. The improved understanding of the host antiviral responses may help develop safe and effective immunotherapeutic strategies against COVID-19 in the foreseeable future.

Keyword

COVID-19; Comorbidities; Vaccination; Convalescent Serum; Antibodies; Immunotherapy

Figure

• 

  Fig. 1 Structure of SARS-CoV-2 and potential antibody targets.SARS-CoV-2 has four major targets: the N protein covering the viral ribonucleic acid (RNA), the E protein encompassing the viral envelope, the M protein protruding from the cell membrane and the S protein that engages with the angiotensin-converting enzyme 2 receptor on host cells. Specific neutralizing IgG antibodies to N and S proteins, which are less prone to mutate, may provide successful host immunity; these are also potential targets for future vaccination strategies (A). Antibodies to E and M proteins, which often mutate, may not be protective against SARS-CoV-2. Cross-reactive antibodies which are generated in response to measles and other known viral vaccines may offer a degree of anti-SARS-CoV-2 protection (B). Intravenous immunoglobulin and neutralizing antibodies in convalescent serum may block the virus entry to host cells (C) and dampen hyperinflammation (D).SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, N = nucleocapsid, E = envelope, M = membrane, S = spike.

Reference

1. Worldometer. COVID-19 coronavirus pandemic. Updated 2020. Accessed May 1, 2020. https://www.worldometers.info/coronavirus/.

2. Ferdinand KC, Nasser SA. African American COVID-19 mortality: a sentinel event. J Am Coll Cardiol.

3. She J, Liu L, Liu W. COVID-19 epidemic: disease characteristics in children. J Med Virol.

4. Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020; 12(3):E254. PMID: 32106567.

5. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. Forthcoming 2020.

6. Licciardi F, Giani T, Baldini L, Favalli EG, Caporali R, Cimaz R. COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. Pediatr Rheumatol Online J. 2020; 18(1):35. PMID: 32321540.

7. Hedrich CM. COVID-19 - Considerations for the paediatric rheumatologist. Clin Immunol. 2020; 214:108420. PMID: 32283324.

8. Tagarro A, Epalza C, Santos M, Sanz-Santaeufemia FJ, Otheo E, Moraleda C, et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. Forthcoming 2020.

9. Dashraath P, Wong JL, Lim MX, Lim LM, Li S, Biswas A, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol. Forthcoming 2020.

10. Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during pregnancy and possible vertical transmission. Am J Perinatol. Forthcoming 2020.

11. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. Forthcoming 2020.

12. Favalli EG, Agape E, Caporali R. Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol. Forthcoming 2020.

13. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. Forthcoming 2020.

14. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. Forthcoming 2020.

15. Zbinden-Foncea H, Francaux M, Deldicque L, Hawley JA. Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2? Obesity (Silver Spring). Forthcoming 2020.

16. Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. Scientific hypotheses: writing, promoting, and predicting implications. J Korean Med Sci. 2019; 34(45):e300. PMID: 31760713.

17. Salman S, Salem ML. Routine childhood immunization may protect against COVID-19. Med Hypotheses. 2020; 140:109689. PMID: 32240961.

18. Baskar PV, Collins GD, Dorsey-Cooper BA, Pyle RS, Nagel JE, Dwyer D, et al. Serum antibodies to HIV-1 are produced post-measles virus infection: evidence for cross-reactivity with HLA. Clin Exp Immunol. 1998; 111(2):251–256. PMID: 9486389.

19. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020; 24:91–98. PMID: 32257431.

20. Pradhan P, Pandey AK, Akhilesh Mishra A, Gupta P, Tripathi PK, Menon MB, et al. WITHDRAWN: uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag. Updated 2020. Accessed May 1, 2020. https://www.biorxiv.org/content/10.1101/2020.01.30.927871v1. DOI: 10.1101/2020.01.30.927871.

21. Nutho B, Mahalapbutr P, Hengphasatporn K, Pattaranggoon NC, Simanon N, Shigeta Y, et al. Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019?: atomistic insights into the inhibitory mechanisms. Biochemistry. Forthcoming 2020.

22. Zhao J, Liao X, Wang H, Wei L, Xing M, Liu L, et al. Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV. Clin Infect Dis. Forthcoming 2020.

23. Ayoub BM. COVID-19 vaccination clinical trials should consider multiple doses of BCG. Pharmazie. 2020; 75(4):159. PMID: 32295694.

24. Sala G, Miyakawa T. Association of BCG vaccination policy with prevalence and mortality of COVID-19. Updated 2020. Accessed May 1, 2020. https://www.medrxiv.org/content/10.1101/2020.03.30.20048165v1.full.pdf. DOI: 10.1101/2020.03.30.20048165.

25. ClinicalTrials.gov. Reducing health care workers absenteeism in COVID-19 pandemic through BCG vaccine (BCG-CORONA). Updated 2020. Accessed May 1, 2020. https://clinicaltrials.gov/ct2/show/NCT04328441.

26. ClinicalTrials.gov. BCG vaccination to protect healthcare workers against COVID-19 (BRACE). Updated 2020. Accessed May 1, 2020. https://clinicaltrials.gov/ct2/show/NCT04327206.

27. Mendelson M. Could enhanced influenza and pneumococcal vaccination programs help limit the potential damage from SARS-CoV-2 to fragile health systems of southern hemisphere countries this winter? Int J Infect Dis. 2020; 94:32–33. PMID: 32194236.

28. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79(1):39–52. PMID: 31413005.

29. Jawhara S. Could Intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020; 21(7):E2272. PMID: 32218340.

30. Díez JM, Romero C, Gajardo R. Currently available intravenous immunoglobulin (Gamunex®-C and Flebogamma® DIF) contains antibodies reacting against SARS-CoV-2 antigens. Updated 2020. Accessed May 1, 2020. https://www.biorxiv.org/content/10.1101/2020.04.07.029017v2. DOI: 10.1101/2020.04.07.029017.

31. Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. Dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020; 7(3):a102.

32. Fauci AS, Lane HC, Redfield RR. COVID-19 - navigating the uncharted. N Engl J Med. 2020; 382(13):1268–1269. PMID: 32109011.

33. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020; 130(4):1545–1548. PMID: 32167489.

34. Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020; 323(16):1561.

35. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered 2 patient cohort and their implications. Updated 2020. Accessed May 1, 2020. https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v2.full.pdf. DOI: 10.1101/2020.03.30.20047365.

36. Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. J Infect. 2020; 80(5):e14–e17. PMID: 32171867.

37. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis.

38. Mallapaty S. Will antibody tests for the coronavirus really change everything? Nature. 2020; 580(7805):571–572. PMID: 32313159.

39. Zhang L, Pang R, Xue X, Bao J, Ye S, Dai Y, et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany NY). 2020; 12(8):6536–6542. PMID: 32320384.

40. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020; 323(16):1582.

41. Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. J Infect Dis.

42. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020; 117(17):9490–9496. PMID: 32253318.

43. Zhao Q, He Y. Challenges of convalescent plasma therapy on COVID-19. J Clin Virol. 2020; 127:104358. PMID: 32305026.

44. Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020; 38(1):10–18. PMID: 32134278.

45. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382–385. PMID: 32065055.

46. Chen X, Li R, Pan Z, Qian C, Yang Y, You R, et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol.